<DOC>
	<DOCNO>NCT00486720</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability vorinostat patient low risk Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>Phase IIa Vorinostat ( MK0683 , Suberoylanilide Hydroxamic Acid ( SAHA ) ) Study Lower Risk Myelodysplastic Syndromes ( 0683-064 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient male female , least 18 year age low intermediate1 risk Myelodysplastic Syndrome ( MDS ) define International Prognostic Scoring System Patient previously untreated disease , receive one prior treatment regimen lowerrisk Myelodysplastic Syndrome Patient performance status equal le 2 Eastern Cooperative Oncology Group Performance Scale Patient must adequate organ function Patient clinical evidence Central Nervous System ( CNS ) leukemia Patient pregnant breastfeeding , expect conceive within project duration study Patient prior treatment histone deacetylase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>